Why are monoclonal antibodies considered to be attractive candidates as effective anti-cancer agents? Chemotherapy has been used for the treatment of advanced malignancies for nearly 40 years. This relatively nonspecific treatment exploits either altered kinetics or altered enzymology of cancer cells to achieve its effect. The problem with this approach is that cancer cell kinetics and enzymology are not always so different in cancer cells as compared with normal cells. Malignant cells are frequently in the Go phase of the cell cycle and are therefore not accessible to the chemotherapy agents which are administered. Finally, the issue of tumor heterogeneity comes up again and again in the consideration of all cancer therapy strategies. Some cancer cells may be responsive to treatment, but others are not. The resistant clones grow out and thus have a selective survival advantage. An added wrinkle to this obstacle is the induction by chemotherapy of pleiotropic drug resistance: cancer cells which develop resistance to one chemotherapy agent may become resistant to many different drugs . Immunotherapy, which depend s upon recognition of cell surface structures to allow alternative conceptual approach to chemotherapy. Monoclonal antibody therapy research is now in an early experimental phase, but has shown promise.
Antibodies are proteins which attach to foreign object s (i.e ., antigens) in the host organism to target them for elimination by the cellular or cytolytic components of the host immune system. Each antibody possesses an isotype , which is defined by the composition of its Fe portion. The IgG2 a and IgG 3 murine isotypes appear to have the most potent biological effects. Other murine isotypes po ssess little biologic activity but do retain binding charac-tenstics , and are best suited for tumor imaging or as delivery ve h ic le s for cytotoxic molecules to neoplastic cells . There are many different antigens on a cancer cell's surface that an antibody could identify and thus target the cell for destruction but, there are very few examples of tumor specific antigens . Most of the antigens which have been identified by monoclonal antibodies are merely tumor-associated, meaning that these structures, which are usually glycoproteins, are present on normal cells, but are expressed more frequently by the malignant cell population.
Once an antibody has coated a tumor target, it can cooperate with a variety of effector cells to induce target cell destruction. Almost certainly, this process involves a very delicate orchestration of a variety of different effector mechanisms . Differing antigens and antibodies may each stimulate the activity of different populations of effector cells. The mechanism by which most targeted malignant cells are killed by currently available antibodies is known as antibody dependent cytotoxicity. An antibody coats its target antigen and the Fe portion, or non-binding portion of the antibody, is then partially ingested by the Fe receptor on the surface of the effector cell, thus bringing the effector cell into contact with the tumor.
Antibodies might also effect continuing tumor cell lysis via a unique amplification system called the anti-idiotype network . Each antibody stimulates the production of an anti-antibody whose binding portions identify the original antibody's binding sites; thus these anti-antibodies define the anti-idiotype , or mirror image of the binding sites of the original antibody. In this way, a series of mirror images of the original idiotype can be made. Some of these anti-idiotype antibodies will have binding properties which are similar to the original antibody. This may provide for continued binding of a particular target on an malignant cell long after the original antibody has been eliminated from the host system . Monoclonal antibodies have special features which give them advantages over conventional antisera, which contain a mixture of different antibodies . Polyclonal antisera thus contain variable amounts of the desired antibody and cannot be relied upon to provide identical binding and effector cell activating characteristics over any period of time , since the composition of antibodies may vary with each batch of anti serum. Thi s loss of reproducibility is a major obstacle which is overcome by monoclonal antibod y technology. A monoclonal antibody is produced in pure form ; so only the desired antibody is then administered as therapy. Since a monoclonal antibody can be generated in culture for many years, reproducibility of a therapeutic product is now a realistic expectation.
Monoclonal antibody generation begins with the injection of antigens into mice. The animals make antibodies to that antigen, and their spleens , which contain B lymphocytes committed to antibody production, are removed. The spleen cells are fused with immortal murine myeloma cells , usually using polyethylene glycol (PEG). These hybrid cell fusion products have the myeloma cells' capacity for selfregeneration and the spleen cells' ability to secrete immunoglobulin and survive in a selection medium which is toxic for unfused myeloma cells. The unfused spleen cells die in this medium as well since they do not have the capacity to replicate. The fusion products which survive make a variety of antibodies. These hybrid cells are allowed to recover from the fusion procedure and to grow in 96 well plates for a period of time . The cell supernatants are tested for the production of immunoglobulins which bind to the immunizing antigen. When the well which contain cells that -nake antibodies of interest are identified, the cells from each such well are dispersed into many new wells so that only one cell (or less) is in each well. These immortal cells will divide and secrete more antibody, and the subclones of cells which have optimal antibody production characteristics can be identified and expanded in culture. Once the antibodies have been produced in large quantity and have been purified to near-homogeneity, the antibodies' binding characteristics and ability to interact with the effector mechanisms of Supernatants tested for production of antibody whic h bi nd s to the immunizing antigen.
MONOCLONAL ANTIBODIES
the immune system to induce specific tumor lysis can be evaluated in vitro.
Once a tumor-binding monoclonal antibody with appropriate in vitro characteristics has been identified, it is tested in an experimental in vivo model. The most commonly used model is the nude mouse system. Nude mice are deficient in T lymphocytes and, in contrast to immunologically normal mice, accept human tumor xenografts. In this system, human tumor xenografts derived from malignant cells growing in tissue culture are injected into the mice. Antibody is then administered in an attempt to either delay the growth of the tumor or actually cure the mice. Antibodies which are potent in both in vitro and in vivo systems are candidates for therapeutic use in malignancies which express the appropriate target antigen.
Monoclonal antibodies have diagnostic and therapeutic clinical applications. Monoclonal antibodies are used in a variety of serologic tests in the clinical pathology laboratory and are used routinely in immunohistology studies. These in vitro applications are supplemented by in vivo nuclear medicine imaging with radiolabeled anti-tumor monoclonal antibodies. This promising diagnostic modality is still in its embryonic phase, but it seems likely that specific indications for this form of diagnostic imaging will evolve over time.
There are two broad areas of potential therapeutic applications of monoclonal antibodies -in vivo administration or in vitro purging of tumor cell populations from bone marrow cell preparations prior to infusing the cells into patients undergoing autologous bone marrow transplantation procedures. This latter approach, while very interesting, will not be discussed further in this paper. Clinical trials with monoclonal antibodies have a very high profile and a great deal of appeal to the general public and to referring physicians. However, we have a long way to go before this strategy is consistently effective (Table) . One obstacle to success is antigenic heterogeneity within tumor masses. Nearly all of the clinically available monoclonal antibodies bind to tumorassociated antigens present on cell surfaces. None of these antigens are expressed on every single tumor cell, so a variable percentage of cells in a particular deposit will be bound by antibody. Different tumor deposits in the same patient may have varying patterns of antigen expression and it is not uncommon to see, for example, a liver metastasis that expresses the target antigen whereas a sub- cutaneous nodule has no expression. One might predict, therefore, a mixed clinical response to therapy with a particular antibody in this setting. One solution to this problem may be the use of a mixture of tumor binding monoclonal antibodies.
Another problem is the apparent inaccessibility of antigens to antibody therapy, even if these antigens are expressed by conventional immunohistologic criteria. This appears to be a physiologic rather than immunologic obstacle, and is probably due to vascular supply variability and local tissue factors which are, as yet, poorly understood. In addition, antibody may be removed by the reticuloendothelial system and never migrate to the tumor sites. To illustrate the magnitude of this bioavailability problem, Dr. Philip Moldofsky at the Fox Chase Cancer Center has performed imaging studies using 131-iodine-Iabeled monoclonal antibody fragments and has shown that no more than 0.1% of the total administered dose of iodine is ever concentrated at the tumor sites. Clearly this problem represents a formidable obstacle to strategies which depend upon antibodydirected delivery of toxic payloads to tumors.
Another obstacle is the variable biologic effect associated with binding of the antibody. The mere fact that an antibody binds to a neoplastic cell does not mean that this target will be destroyed. Strategies which amplify the immunologic response to binding by antibody might circumvent the relatively low efficiency of binding following antibody administration.
Finally, the development of an antimouse immunoglobulin may limit the duration of therapy with murine monoclonal antibodies. This response causes two problems. First, the development of neutralizing antibodies will prevent therapeutic antibodies from trafficking to the tumor deposits. The second problem is one of anaphylaxis, probably due to IgE antibodies. Until it is clear that a particular antibody therapy strategy is really effective and retreatment is thus desirable, this is a secondary issue. Of course, the development of human monoclonal antibodies, which has, up to now, been difficult to accomplish, would likely circumvent this problem entirely.
Despite these obstacles, there have been some exciting clinical studies with monoclonal antibodies. The first trial ever done which demonstrated some efficacy of monoclonal antibody therapy was performed by Levy and his colleagues at Stanford University in 1981. They treated patients with a variety of B cell lymphomas with personalized anti-idiotype monoclonal antibodies. These lymphoma cells express the idiotype, or binding signature, of the antibody that they are programmed to generate on their cell surfaces. Since these malignancies are clonal, all of the lymphoma cells in a given patient should express the same idiotype. By using those cells that bear the idiotype signature to immunize animals, anti-idiotype monoclonal antibodies which are actually tumor-specific can be generated. Eleven patients were treated in this fashion, each with personalized monoclonal antibodies. Eight doses of antibody were administered over four weeks without toxicity. The first patient went into a sustained complete remission. Five other patients experienced transient partial responses. These short durations were caused by a phenomenon known as antigenic modulation. With repeated therapy, the surviving lymphoma cells failed to express the surface idiotype and thus evaded antibody recognition. These seminal observations demonstrated that if sufficient antibody could be delivered to target neoplasms, there was a hope for some clinical antitumor effect.
The first report of successful therapy using monoclonal antibodies directed against tumor-associated antigens came from Houghton and colleagues at Memorial Sloan Kettering Cancer Center. The R24 antibody binds to the GD 3 gangliosides expressed by melanomas, and exerts its anti-tumor activity by cellular and possibly complement fixation mechanisms. This Phase I trial demonstrated that toxicity of this therapy was related to the total dose administered. Four of the 21 patients in this trial experienced objective responses, and one of these was a complete response. The durations of response were not insignificant, ranging from six to 44 months. This important study demon-strated that tumor-associated antigens could provide suitable targets for therapy with monoclonal antibodies under some circumstances.
Another trial that demonstrates the promise of monoclonal antibodies has been reported. This study differs from the others in that the antibodies were used as delivery vehicles for a toxic payload. Xomazyme is a anti-melanoma antibody which is conjugated with the ricin A chain. Ricin is an extremely potent toxin which is composed of two chains, termed A and B. The B chain attaches the ricin molecule to the cell surface, while the A chain mediates cell lysis after the toxin is incorporated into the cellular cytoplasm. Monoclonal antibodies may substitute for the B chain so that the antibody delivers the ricin A chain to the malignant cell target. Theoretically, this is a highly specific process. Xomazyme was highly effective in in vitro and in vivo experimental models. A Phase I clinical trial of this agent was performed with twenty-two patients. The toxicity was interesting in that high doses were associated with hypoalbuminemia, weight gain, malaise, myalgias, anorexia and fevers. This pattern suggests reversible inhibition of hepatic protein synthesis, which might imply unwanted hepatic cellular ingestion of ricin A chain due to hepatic uptake of the immunoconjugate. Of the twenty-two evaluable patients there were one complete response, four partial responses, five with stable disease and 12 with progressive disease. The nonresponders had more extensive disease than did the responders. These responses occurred slowly, a surprising finding since one might expect ricin to cause rapid target cell death. It is possible that this ricin conjugate somehow enhanced antibody dependent cytotoxicity.
At the Fox Chase Cancer Center, we have extensive experience with a monoclonal antibody known as 17-IA which was developed at the Wistar Institute by Koprowski and his colleagues. This antibody has an IgG2a isotype. The anti-tumor cytotoxic effect of this antibody appears to be due to antibody dependent cytotoxicity which is mediated by monocytes. The target antigen that is recognized by this antibody is a tumor-associated glycoprotein antigen expressed preferentially by colorectal, gastric and pancreatic adenocarcinoma cells. The antigen is otherwise poorly characterized despite eight years of intensive investigation. We have treated approximately 170 patients with this anti-In parallel with these studies, efforts to conjugate toxic componds with tumor binding antibodies to create "magic bullets" with clinical actMty will continue. body at the Fox Chase Cancer Center. The antibody can be administered safely, even in very high doses. However, prolonged therapy carries the risk of anaphylactic reactions. When the antibody is administered intravenously, it can be detected in tumor deposits by either immunohistologic or quantitative imaging techniques. Despite occasional clinical responses, this particular antibody has demonstrated no persistent patterns of response. Repeated administration is associated with the development of human anti-mouse immunoglobulin and human anti-17-1A idiotype antibodies, the clinical implications of which are still unclear. While some European investigators have reported better response data with this antibody, these results cannot be confirmed by a number of investigators in this country.
In an attempt to enhance the biologic effects associated with binding of monoclonal antibody 17-1A to its tumor targets, we have treated patients with gamma interferon prior to the antibody therapy. We chose gamma interferon because it enhances monocyte and natural killer cell cytotoxicity and antibody dependent cytotoxicity in vitro. Also, gamma interferon up-regulates the expression of a variety of cellular surface antigens and therefore makes tumor-associated antigens or immune recognition molecules more accessible on the surface of the target and effector cells respectively. In addition, gamma interferon enhances Fe receptor expression in immunologic effector cells. All of these factors suggest that this agent may potentiate the biologic activity of a monoclonal antibody which exerts its action via these mechanisms.
We recently completed a Phase I clinical trial of these two agents. In this study, our goal was to identify a gamma interferon dose range which maximally activated monocyte cytotoxicity and antibody-dependent cytotoxicity without excessive toxicity. Monocytes were purified from peripheral blood samples during gamma interferon therapy and assayed for their ability to lyse colon carcinoma cells in vitro, with and without 17-1A,which binds to this colon carcinoma cell line. Wefound that the toxicity of gamma interferon was dose-related, but that low doses of this agent were as effective as high doses in enhancing non-specific monocyte cytotoxicity. Furthermore, low doses of gamma interferon caused an enhancement of monocyte-mediated antibody dependent cytotoxicity, while high doses did not augment, and may have depressed this parameter. Therefore, we have concluded that low doses of interferon were preferable to attain our pre-treatment goals. If these patients' monocytes were incubated with additional gamma interferon in vitro prior to using them in the tumor cell killing assay, these effects were actually magnified. These results suggest that a combination of low dose gamma interferon therapy, combined with ex vivo activation of monocytes by this agent, potentiates monocytemediated lysis maximally in patients treated with 17-1A. Additional clinical trials which will critically test our findings are currently underway at a number of centers in this country.
The clinical studies which have been discussed point the way to the development of cohesive strategies which exploit antibody targeting of malignant cells. Along with gamma interferon, other immune potentiators such as interleukin-2 will be studied. In parallel with these studies, efforts to conjugate toxic compounds with tumor binding antibodies to create "magic bullets" with clinical activity will continue. While the solutions will not be easy, this field appears ready to overcome at least some of the obstacles to its success and find a role in the therapy of human cancer.
